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Abstract
Background: Fumonisin B1 is a cancerogenic mycotoxin produced by Fusarium verticillioides and other fungi.
Sphingopyxis sp. MTA144 can degrade fumonisin B1, and a key enzyme in the catabolic pathway is an
aminotransferase which removes the C2-amino group from hydrolyzed fumonisin B1. In order to study this
aminotransferase with respect to a possible future application in enzymatic fumonisin detoxification, we attempted
expression of the corresponding fumI gene in E. coli and purification of the enzyme. Since the aminotransferase
initially accumulated in inclusion bodies, we compared the effects of induction level, host strain, expression
temperature, solubility enhancers and a fusion partner on enzyme solubility and activity.
Results: When expressed from a T7 promoter at 30°C, the aminotransferase accumulated invariably in inclusion
bodies in DE3 lysogens of the E. coli strains BL21, HMS174, Rosetta 2, Origami 2, or Rosetta-gami. Omission of the
isopropyl-beta-D-thiogalactopyranoside (IPTG) used for induction caused a reduction of expression level, but no
enhancement of solubility. Likewise, protein production but not solubility correlated with the IPTG concentration in
E. coli Tuner(DE3). Addition of the solubility enhancers betaine and sorbitol or the co-enzyme pyridoxal phosphate
showed no effect. Maltose-binding protein, used as an N-terminal fusion partner, promoted solubility at 30°C or
less, but not at 37°C. Low enzyme activity and subsequent aggregation in the course of purification and cleavage
indicated that the soluble fusion protein contained incorrectly folded aminotransferase. Expression in E. coli
ArcticExpress(DE3), which co-expresses two cold-adapted chaperonins, at 11°C finally resulted in production of
appreciable amounts of active enzyme. Since His tag-mediated affinity purification from this strain was hindered by
co-elution of chaperonin, two steps of chromatography with optimized imidazole concentration in the binding
buffer were performed to obtain 1.45 mg of apparently homogeneous aminotransferase per liter of expression
culture.
Conclusions: We found that only reduction of temperature, but not reduction of expression level or fusion to
maltose-binding protein helped to produce correctly folded, active aminotransferase FumI in E. coli. Our results
may provide a starting point for soluble expression of related aminotransferases or other aggregation-prone
proteins in E. coli.
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Background
The aminotransferase FumI from the bacterium Sphin-
gopyxis sp. MTA144 [1] may be useful in a technological
application for detoxification of the mycotoxin fumoni-
sin B1 (FB1). FB1 is the most prevalent member of the
fumonisin mycotoxin family [2], which is predominantly
produced by Fusarium verticillioides (former F. monili-
forme) and F. proliferatum, and frequently found in
maize and maize products from warm climate regions of
the world [3,4]. Since their isolation and structure deter-
mination in 1988 [5,6], the toxic and carcinogenic
effects of fumonisins, in particular FB1, have been
demonstrated in several studies [7-17]. Approaches to
reduce fumonisin contamination in food and feed
included various chemical and physical strategies
[18-24]. However, none of these methods have been
implemented on a large scale, and fumonisins in the
diet still affect the health of livestock [25] and possibly
also of humans. Our technological goal is to provide
fumonisin-degrading enzymes as a feed additive for
detoxification in the gastrointestinal tract of animals.
Genes and enzymes for fumonisin detoxification from
yeast strains [26], an unidentified bacterial strain [27],
and Sphingopyxis sp. MTA144 [1] have previously been
described. The catabolic pathways share the initial
hydrolytic cleavage of the two tricarballylic acid side
chains from C14 and C15 of the main chain of fumoni-
sin B1. The reaction product, hydrolyzed FB1 (HFB1),
has reduced affinity to the primary target of FB1, the
enzyme ceramide synthase [28,29]. However, the amino
group of HFB1 can be acylated by ceramide synthase,
forming toxic metabolites [30,31]. In contrast to the
yeast strains, which use an amino oxidase, Sphingopyxis
sp. MTA144 uses the aminotransferase FumI for deami-
nation of HFB1, resulting in the formation of 2-keto-
HFB1 (Fig. 1). Since this aminotransferase, unlike the
amino oxidase, does not require molecular oxygen, it
may be suitable for HFB1 detoxification in the gastroin-
testinal tract. Therefore we intended to prepare pure
and active recombinant aminotransferase FumI for
studying its technological potential as a feed enzyme.
Initially, we found that expression of a codon-optimized
version of the fumI gene in Pichia pastoris gave very
low enzyme yields, and efforts to obtain active enzyme
by refolding from inclusion bodies isolated from E. coli
remained unsuccessful. Even though the enzyme aggre-
gated in E. coli, the aminotransferase FumI activity was
detectable in clarified cell lysate, which motivated our
strategy of trying to enhance solubility. Several strategies
have been described to obtain soluble expression in
E. coli [32], including the use of solubility-enhancing
fusion tags [33,34], expression at reduced temperature
[35], co-expression of chaperones [36], reduction and
fine-tuning of expression level [37], export to the peri-
plasm [38,39] or change of the cytoplasmic redox poten-
tial for disulfide bond formation [40], consideration of
codon usage [41], optimization of bioprocess para-
meters, or use of dedicated screening tools for finding
conditions for soluble expression [42]. Since factors
leading to recombinant protein aggregation are not only
host-specific but also target protein specific, no univer-
sal remedy for inclusion body formation is available. For
the present report, we explored several approaches of
increasing the yield of soluble and active aminotransfer-
ase FumI in E. coli, including comparison of several E.
coli(DE3) strains, isopropyl-beta-D-thiogalactopyranoside
(IPTG) concentrations and expression temperatures, and
fusion with maltose-binding protein (MBP). The best
yield, sufficient for His tag-mediated purification using
an optimized protocol, was obtained by expression in
E. coli ArcticExpress(DE3) at low temperature.
Results
Comparison of E. coli(DE3) strains
The combinations of different expression vectors and
E. coli strains used in this work are listed in Table 1.
Since the fumI gene contains a restriction site for NcoI,
pET vectors that enable gene insertion at an NdeI site
covering the translation initiation codon were chosen.
Initially, the fumI gene was cloned into vector pET-30a
Figure 1 The reaction catalyzed by aminotransferase FumI. The enzyme transfers the 2-amino group from hydrolyzed fumonisin B1 (HFB1,
2-Amino-12,16-dimethylicosane-3,5,10,14,15-pentol) to pyruvate, producing 2-keto-HFB1 (3,5,10,14,15-Pentahydroxy-12,16-dimethylicosane-2-one)
and alanine.
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(+) for low background expression based on the T7lac
promoter. When the gene was expressed in E. coli BL21
(DE3) by induction with 1 mM IPTG at 37°C, most of
the aminotransferase was found in the insoluble fraction
of cell lysate (Fig. 2). Since our efforts to refold the ami-
notransferase from solubilized inclusion bodies by dialy-
sis or dilution remained unsuccessful, we attempted to
increase the yield of soluble, correctly folded protein
produced in recombinant E. coli. We had previously
observed when using other recombinant proteins that E.
coli(DE3) strains can produce considerable amounts of
recombinant protein from a gene cloned under control
of a T7 promoter even in the absence of IPTG. So the
fumI gene was cloned into vector pET-3a, which does
not contain a lac operator sequence downstream of the
T7 promoter. E. coli BL21(DE3) harboring plasmid pET-
3a-AT or pET-3a-HISAT was grown at 37°C without
IPTG for low level recombinant gene expression, which
might be beneficial for correct folding. However, amino-
transferase FumI still accumulated in inclusion bodies.
Addition of 2.5 mM betaine or 600 mM sorbitol, which
were previously proposed as solubility enhancers [43], to
LB medium for expression failed to increase the yield of
soluble aminotransferase. Pyridoxal phosphate, which is
a co-enzyme of aminotransferase FumI, likewise showed
no effect when added to the medium at a concentration
of 1 mM. Subsequently, we reduced the expression tem-
perature to 30°C, and compared the E. coli strains BL21
(DE3), HMS174(DE3), Tuner(DE3), Rosetta-gami(DE3),
Origami 2(DE3) and Rosetta 2(DE3) with respect to
expression of active FumI. However, none of these
Table 1 Recombinant E. coli strains used in this work. AT or AT144 was used for fumI in the vector names
Host strain Recombinant
Plasmid
Fusion tag Recombinant strain
E. coli BL21(DE3) pET-3a-AT - E. coli BL21(DE3) pET-3a-AT
pET-3a-HISAT N-terminal 6xHis tag E. coli BL21(DE3) pET-3a-HISAT
pET-30a-AT144 - E. coli BL21(DE3) pET-30a-AT144
pMAL-AT144 MBP E. coli BL21(DE3) pMAL-AT144
E. coli HMS174(DE3) pET-3a-HISAT N-terminal 6xHis tag E. coli HMS174(DE3) pET-3a-HISAT
pMAL-AT144 MBP E. coli HMS174(DE3) pMAL-AT144
E. coli Origami 2(DE3) pET-3a-HISAT N-terminal 6xHis tag E. coli Origami 2(DE3) pET-3a-HISAT
pMAL-AT144 MBP E. coli Origami 2(DE3) pMAL-AT144
pMAL E. coli Origami 2(DE3) pMAL
E. coli Rosetta 2(DE3) pET-3a-HISAT N-terminal 6xHis tag E. coli Rosetta 2(DE3) pET-3a-HISAT
E. coli Rosetta-gami(DE3) pET-3a-HISAT N-terminal 6xHis tag E. coli Rosetta-gami(DE3) pET-3a-HISAT
E. coli Tuner(DE3) pET-3a-HISAT N-terminal 6xHis tag E. coli Tuner(DE3) pET-3a-HISAT
E. coli ArcticExpress(DE3) pET-30a-AT144HIS C-terminal 6xHis tag E. coli ArcticExpress(DE3) pET-30a-AT144HIS
pET-3a-HISAT N-terminal 6xHis tag E. coli ArcticExpress(DE3) pET-3a-HISAT
pET-3a-AT - E. coli ArcticExpress(DE3) pET-3a-AT
Figure 2 Expression of fumI in E. coli BL21(DE3) at 37°C. SDS-
PAGE (12% polyacrylamide, GelCode Blue staining) analysis of
fractions of cell lysate of E. coli BL21(DE3) expressing fumI from
vector pET-30a-AT144 by induction with 1 mM IPTG at 37°C. Lane
M, molecular mass marker; Lane T, total cell lysate; Lane S, soluble
fraction of cell lysate; Lane I, insoluble fraction. The molecular mass
of aminotransferase FumI (46.3 kDa) is indicated.
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experiments resulted in the expression of significant
amounts of soluble FumI, both when 0.4 mM IPTG or
no induction with IPTG were used, and the recombi-
nant His-tagged protein was only seen in the insoluble
fraction (Fig. 3A, B). When using E. coli Tuner(DE3),
which is a lacZY deletion mutant that allows a concen-
tration-dependent level of induction with IPTG since
the permease LacY is lacking, a correlation between
IPTG concentration and expression level was observed.
Yet again, reduction of the expression level failed to
enhance the yield of soluble aminotransferase (Fig. 3C).
Expression and purification of aminotransferase FumI as
fusion protein with maltose-binding protein
Several examples have been reported, in which the use
of MBP as a fusion partner effectively promoted the
expression of soluble recombinant protein in E. coli
[44-47]. In order to test this possibility for FumI, we
constructed plasmid pMAL-AT144 for production of
the MBP-FumI fusion protein. When the expression
temperature was 37°C, the fusion protein accumulated
in the insoluble fraction of cell lysates of E. coli BL21
(DE3), HMS174(DE3) and Origami 2(DE3). However,
when the expression temperature was reduced to 30°C
or room temperature, and the expression time was con-
comitantly extended from 2 to 20 h, E. coli Origami 2
(DE3) produced some of the fusion protein in soluble
form (Fig. 4). As judged from the intensities of the pro-
tein bands, expression at room temperature yielded
more soluble fusion protein than at 30°C. The fusion
protein was subsequently purified by affinity chromato-
graphy on dextrin sepharose resin (Fig. 5), and approxi-
mately 0.8 mg of purified MBP-FumI fusion protein
could be obtained per liter of expression culture. When
the sample was analyzed after dialysis against the buffer
required for recombinant enterokinase cleavage, part of
the fusion protein was found to be aggregated. However,
after cleavage with recombinant enterokinase, both
fusion partners were found in the soluble fraction (Fig.
6A). The enzymatic activity of the fusion protein was
lower than that of the purified His-tagged enzyme and
did not increase upon separation of the fusion partners
with enterokinase (Fig. 6B).
Expression in E. coli ArcticExpress(DE3) and His
tag-mediated affinity purification
As described above, the fraction of soluble recombinant
protein increased when the expression temperature was
reduced. Therefore, we attempted a further reduction of
temperature by expressing fumI in E. coli ArcticExpress
(DE3). This strain heterologously produces chaperonin
Cpn60 and co-chaperonin Cpn10 from the psychrophilic
bacterium Oleispira antarctica, which both show high
protein refolding activities at 4°C to 12°C and allow E.
coli to grow at high rates (0.28 to 0.45 h-1) at 4°C to 15°
C [48]. Vector pET-30a-AT144HIS was used for expres-
sion of fumI in E. coli ArcticExpress(DE3) at 11°C for 24
h. Most of the gene product still aggregated to insoluble
inclusion bodies, however, as judged from the intensities
of protein bands and enzyme activity measurements,
more soluble protein was obtained when compared to
expression from the same vector in E. coli BL21(DE3) at
37°C for 3 h (Fig. 7). When we purified recombinant
aminotransferase from clarified cell lysates by immobi-
lized nickel affinity chromatography, foreign protein co-
eluted with the His-tagged enzyme. This protein was
Figure 3 Comparison of E. coli(DE3) host strains and effect of IPTG concentrations on FumI production at 30°C. Western blot (anti-His6-
antibody; from 12% polyacrylamide SDS-PAGE gels) analysis of N-terminally 6xHis-tagged aminotransferase FumI. The fumI gene was expressed
in E. coli BL21(DE3) (A), E. coli HMS174(DE3) (A), E. coli Rosetta 2(DE3) (B), E. coli Rosetta-gami(DE3) (B) and E. coli Tuner(DE3) (C) from vector pET-
3a-HISAT at 30°C without (-) and with addition of IPTG (10 μM, 50 μM, 100 μM, 400 μM). Lane S, soluble fraction of cell lysate; Lane I, insoluble
fraction; Lane M, molecular mass marker. The arrow indicates the band corresponding to the molecular mass of His-tagged aminotransferase
FumI (47.5 kDa).
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likely to be Cpn60 because of its molecular mass, and
because chaperonins are known to be co-purified with
various proteins when using immobilized metal affinity
chromatography (IMAC) [49-51]. In order to obtain
homogenous enzyme preparations, variation of the imi-
dazole concentration in the binding buffer was studied.
Co-purification of Cpn60 could be circumvented when
using 60 mM imidazole in the binding buffer, while
100 mM imidazole prevented binding of both Cpn60
and His-tagged aminotransferase to the chromatography
matrix (Fig. 8).
For the preparation of larger amounts of FumI, E. coli
ArcticExpress(DE3) harboring pET-30a-AT144HIS was
grown in 1 l of modified M9ZB medium, expression was
done for 24 h at 11°C, and a concentration of 60 mM
imidazole in the binding buffer was used for subsequent
IMAC. Two IMAC steps using conditions as described
above gave an enzyme preparation that was apparently
Figure 4 Solubility of MBP-FumI fusion protein produced in E. coli(DE3) at 30°C or 23.5°C. SDS-PAGE (10% polyacrylamide, silver staining)
analysis of total (T), soluble (S) and insoluble (I) fractions of cell lysates of E. coli Origami 2(DE3) after expression of MBP-FumI fusion protein (89.5
kDa) from vector pMAL-AT144, or MBP (50.9 kDa) from vector pMAL (pMAL-c2E, no insert). Expression was done for 20 h at room temperature
(RT, 23.5°C) (A) or 30°C (B). Lane M, molecular mass marker.
Figure 5 Purification of MBP-FumI fusion protein by affinity chromatography. Chromatogram (A) of affinity chromatography of MBP-FumI
fusion protein (89.5 kDa) on dextrin sepharose and elution with 50 mM maltose, and analysis of fractions by SDS-PAGE (10% polyacrylamide,
GelCode Blue staining) (B). Lane CL, clarified cell lysate; lane 2, fraction from 2 to 2.5 ml; lane 23, fraction from 23 to 23.5 ml and so forth; lane
M, molecular mass marker.
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Figure 6 Enterokinase cleavage and aminotransferase activity of purified MBP-FumI fusion protein. (A) Total (T), soluble (S) and insoluble
(I) fractions of purified MBP-FumI fusion protein before addition of recombinant enterokinase (0 h rEK), after 6 h and after 24 h incubation with
recombinant enterokinase were subjected to SDS-PAGE (10% polyacrylamide, GelCode Blue staining). Lane M, molecular mass marker. The
molecular masses of MBP (42.6 kDa), FumI (46.9 kDa) and the fusion protein (89.5 kDa) are indicated. (B) Enzyme activity of purified MBP-FumI
fusion protein after incubation with (+ rEK) or without (Ø rEK) recombinant enterokinase. For comparison, 6xHis-tagged aminotransferase (FumI-
HIS) purified from E. coli ArcticExpress(DE3) by affinity chromatography was included. Protein concentration was 20 μg/ml for each sample.
Samples were incubated with 15 μM HFB1 in 20 mM Tris-HCl buffer (pH 8.0) at 25°C, and initial enzyme velocities, based on HFB1 deamination,
were plotted.
Figure 7 Comparison of solubility and activity of FumI produced in E. coli strains ArcticExpress(DE3) at 11°C and BL21(DE3) at 37°C.
Aminotransferase FumI showed a higher amount of soluble enzyme in a Western blot (anti-His6-antibody; from 12% polyacrylamide SDS-PAGE
gel) (A) and higher enzyme activity (B) when produced in E. coli ArcticExpress(DE3) at 11°C compared with E. coli BL21(DE3) at 37°C. Both host
strains harbored plasmid pET-30a-AT144HIS for expression of fumI with a C-terminal 6xHis tag. (A) The molecular mass of aminotransferase FumI-
HIS (48.3 kDa) is shown; (S) soluble and (I) insoluble fractions of E. coli cell lysates. (B) Initial enzyme velocities based on HFB1 deamination.
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Figure 8 Purification of C-terminally 6xHis-tagged aminotransferase FumI by nickel affinity chromatography. Cell extract of E. coli
ArcticExpress(DE3) [pET-30a-AT144HIS] after production of FumI-HIS (48.3 kDa) was subjected to nickel affinity chromatography using 20 mM (A),
60 mM (B) or 100 mM (C) imidazole in binding buffer. SDS-PAGE analysis (12% polyacrylamide, Coomassie Brilliant Blue stained) of samples
corresponding to these chromatograms show the clarified cell lysate that was applied to the column (CL), samples of the 1-ml fractions that
eluted after the indicated volume, and a molecular mass marker (M).
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homogenous as analyzed by SDS-PAGE (Fig. 9). When
using these conditions both for expression and purifica-
tion, approximately 1.45 mg of purified aminotransferase
FumI could be obtained per liter of expression culture.
Discussion
The use of feed enzymes for gastrointestinal detoxifica-
tion of fumonisins may be a practical solution for ameli-
orating the negative health effects in animal nutrition
caused by fumonisin-contaminated maize, which is fre-
quently encountered in the warmer regions of the world
[3]. Detoxification of mycotoxins by biodegradation with
specific microorganisms has previously been proposed
[52-54]. However, application of one of the known yeast
[26] or bacterial [1,27,55] strains capable of fumonisin
catabolism as a feed additive would require thorough
investigation of possible feed safety issues, and pose the
technological challenge of providing viable, yet shippable
and storable microbes with sufficient activity for fast
fumonisin degradation in the gastrointestinal tract of
domestic animals. In comparison, enzymatic detoxifica-
tion would be a safe and effective alternative, if the spe-
cific enzymes can be produced with high yield in
microbial cell factories, and if they are active in the gas-
trointestinal tract. Several enzymes, including phytase
[56], are commercially provided as feed additive. In
order to evaluate whether the aminotransferase FumI
encoded by the fumI gene of Sphingopyxis sp. MTA144
[1] would be active under the conditions in the
gastrointestinal tract, or in steps of feed and possibly
also food processing, it was essential to have sufficient
amounts of purified enzyme preparations for subsequent
studies available. The transition from the unfolded poly-
peptide to the correctly folded native state may be diffi-
cult for FumI, since we consistently failed to produce
active enzyme by refolding of inclusion bodies using
several protocols and including co-enzyme, substrate
and co-substrate. This ineptness in folding could also be
a reason why expression of a codon-optimized version
of the fumI gene in Pichia pastoris yielded barely detect-
able amounts of the active aminotransferase. Even
though virtually all of the recombinant FumI protein
was found in the sedimenting fraction of cell lysate
in the initial efforts to produce the aminotransferase in
E. coli, low aminotransferase activity was detectable in
clarified cell lysate. This indicated that in principle
correctly folded aminotransferase could be produced in
E. coli, and this was the basis for further exploring
E. coli as host for soluble expression of active
aminotransferase.
Since expression using the vectors pET-3a-AT or
pET-3a-HISAT in the absence of IPTG in E. coli BL21
(DE3) or with varying IPTG concentrations in E. coli
Tuner(DE3) showed no noticeable effect on the amount
or relative proportion of soluble aminotransferase
synthesized, we concluded that solubility of aminotrans-
ferase FumI does not correlate with expression levels.
Promoter strength and expression level are considered
important factors for the cytoplasmic solubility of
recombinant proteins [37], and a correlation between
induction level and solubility of recombinant proteins in
the E. coli cytoplasm has been reported [57]. Our results
are more in line with previous findings that the percent
solubility was independent of recombinant protein con-
centration or production rate [35]. Inclusion body for-
mation did not seem to be caused by the presence and
possible interference with translation of rare codons in
the fumI gene, since expression in E. coli Rosetta 2
(DE3), which supplies tRNAs for the rarely used codons
AUA, AGG, AGA, CUA, CCC and GGA, did not
improve solubility. Efficient folding of recombinant pro-
teins with multiple disulfide bonds in the cytoplasm of
E. coli mutants trxB- (thioredoxin reductase) and gor-
(glutathion reductase) has been reported [40]. Amino-
transferase FumI has eight cysteine residues, but as a
cytoplasmic enzyme in Sphingopyxis sp. MTA144 it is
not predicted by DISULFIND (disulfind.dsi.unifi.it) [58]
to have disulfide bonds. Furthermore, the protein with
the highest sequence identity (glutamate 1-semialdehyde
aminotransferase, 26% identity) in the PDB database
does not contain S-S bridges. Failure to enhance solubi-
lity by expression of fumI in trxB- gor- E. coli Origami 2
(DE3) is in agreement with these considerations. The
Figure 9 SDS-PAGE analysis of purified aminotransferase FumI.
The three lanes show three neighboring fractions of C-terminally
6xHis-tagged aminotransferase FumI (FumI-HIS, 48.3 kDa) after two
consecutive, preparative scale immobilized nickel affinity
chromatography steps using 60-mM imidazole binding buffer. SDS-
PAGE gel (12% polyacrylamide, Coomassie Brilliant Blue stained); M,
molecular mass marker.
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conclusion that fumI is a difficult target for soluble and
active expression in E. coli was further confirmed by the
finding that addition of sorbitol or betaine to the
expression cultures as osmotic modulators had no effect
on aminotransferase activity or solubility. In this respect,
aminotransferase FumI behaved differently to several
recombinant proteins that were reported to show higher
solubility in E. coli in the presence of these osmolytes
[43,59,60].
Together with full-length aminotransferase, shorter
fragments of the enzyme seemed to accumulate upon
fumI gene expression in E. coli. When FumI was pro-
duced with an N-terminal His tag, a peptide of less than
15 kDa, which migrated with the dye front or slightly
slower and which was detectable in the soluble fraction
of some and in the insoluble fraction of all lysates,
reacted specifically with the anti-His6-antibody. Trun-
cated versions of MBP-FumI were also detectable. Since
no such peptides interacted with anti-His6-antibody or
HisTrap chromatography resin when FumI was pro-
duced with a C-terminal His tag, truncated versions
may have been formed by premature translation
termination.
Fusion of aminotransferase to maltose-binding protein,
which was described as more effective in promoting
solubility of recombinant proteins than other fusion
partners [45], helped to prevent aggregation only at
reduced expression temperature but not at 37°C, adding
further evidence for the aggregation-prone nature of
aminotransferase FumI. It has been reported that mal-
tose-binding protein can keep a fusion partner in solu-
tion, even when this partner has not adopted the correct
fold [61,62]. There is evidence that this might in part
also be the case with MBP-FumI. The soluble fusion
protein showed 30-fold lower aminotransferase activity
than a preparation of 6xHis-tagged aminotransferase
purified from cell extract of E. coli ArcticExpress(DE3)
when compared at identical concentrations of recombi-
nant protein. Since the enzymatic activity remained
unchanged after the fusion partners were separated with
recombinant enterokinase, it is possible that the mal-
tose-binding protein fusion does not interfere with ami-
notransferase activity and that the reduced activity
results from incorrectly folded FumI. Further evidence
for this is that some of the fusion protein aggregated
after affinity purification, when the NaCl concentration
was reduced by dialysis and CaCl2 was added for subse-
quent enterokinase cleavage. Under these conditions,
neither MBP nor correctly folded aminotransferase
aggregate. However, enterokinase cleavage transferred
both fusion partners (MBP and FumI) from the sedi-
mentable fraction to the soluble fraction, which does
not fit the assumption that incorrectly folded amino-
transferase caused aggregation of the fusion protein.
A possible explanation could be that the interaction of
enterokinase with the polypeptide chain helped to sepa-
rate, but not refold, aggregates. In experiments that are
not shown we observed that after enterokinase cleavage
the amount of soluble aminotransferase did not match
the amount of MBP in solution, especially when longer
incubation times or higher protein concentrations were
used. Taken together, fusion with maltose-binding pro-
tein seems to have enhanced solubility of aminotransfer-
ase FumI more than it promoted correct folding.
Expression temperature has long been known as a key
factor determining solubility of recombinant proteins in
the cytoplasm of E. coli [35,63], and there are numerous
examples where growth at low temperature increased
solubility. In the case of aminotransferase, a clear effect
of temperature reduction on the levels of soluble recom-
binant protein obtained was only observed when amino-
transferase was fused to maltose-binding protein, or
produced in E. coli ArcticExpress(DE3). The tenfold
increase in enzyme activity that we observed when com-
paring expression from the same plasmid in E. coli BL21
(DE3) at 37°C and E. coli ArcticExpress(DE3) at 11°C
was considerably less than e.g. the more than 150-fold
increase reported by Ferrer et al. (2004) for the expres-
sion of an esterase under similar conditions [64]. Never-
theless, reduction of temperature was the single most
effective measure among the approaches we tested to
enhance solubility and activity of aminotransferase
FumI. Our observation that the co-expressed chaperonin
Cpn60 interfered with affinity purification by IMAC and
that its elution trailed to the fractions of the recombi-
nant target protein has been described before and was
circumvented by changing the binding buffer composi-
tion to reduce the interaction between Cpn60 and the
recombinant protein [49]. We found that co-elution of
Cpn60 could also be avoided by increasing the imidazole
concentration in the binding buffer, although at prepara-
tive scale a repeat of the affinity chromatography step
was necessary to obtain pure target enzyme.
Conclusions
Correct folding of recombinant aminotransferase FumI
in E. coli could not be enhanced by reducing the expres-
sion level or by fusion to maltose-binding protein. Only
lowering the expression temperature to 11°C, enabled by
using E. coli ArcticExpress(DE3) as a host, helped the
formation of active enzyme. The recombinant amino-
transferase FumI thus produced and purified was suffi-
cient to obtain apparently homogeneous protein for
subsequent determination of enzyme characteristics,
kinetic parameters and evaluation of the application
potential as feed enzyme (manuscript in preparation).
Further reduction of expression temperature may
increase the yield of soluble, active enzyme. However,
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if aminotransferase FumI were to be produced on a
technological scale for application as feed enzyme, an
alternative and improved expression system will likely
be required.
Methods
Strains, vectors, chemicals, media
E. coli host strains for gene expression BL21(DE3),
HMS174(DE3), Rosetta 2(DE3), Origami 2(DE3),
Rosetta-gami(DE3) and Tuner(DE3) were purchased
from Novagen (Madison, WI, USA), and strain E. coli
ArcticExpress(DE3) was from Stratagene (La Jolla, CA,
USA). The cloning host strain E. coli XL1-Blue was
from Stratagene. Genetic transformations were per-
formed according to manufacturer’s instructions. Sphin-
gopyxis sp. MTA144 was previously isolated from a soil
sample. The sequence of the fum gene cluster was
deposited under GenBank accession no. FJ426269[1].
Vector pMAL-c2E was purchased from New England
Biolabs (Ipswich, MA, USA), and vectors pET-3a and
pET-30a(+) were obtained from Novagen. All chemicals
were from Sigma (St. Louis, MO, USA). Enzymes were
purchased from Fermentas (St. Leon-Rot, Germany),
except for recombinant enterokinase, which was
obtained from Novagen.
Construction of the expression vectors
Molecular cloning was performed according to standard
procedures [65], and all plasmids were confirmed by
sequencing of the inserts (VBC-Biotech, Vienna, Aus-
tria). The expression vector and host strain combina-
tions used in this work are summarized in Table 1.
pET-3a-AT and pET-3a-HISAT
Cloning of the aminotransferase gene fumI in pET-3a
for expression with or without an N-terminal 6xHis tag
has previously been described [1].
pET-30a-AT144HIS and pET-30a-AT144
The fumI gene was amplified by PCR from a preparation
of genomic DNA of Sphingopyxis sp. MTA144 [1] using
the primers NdeI-fumI-for (5′-CTT ATA CAT ATG
GCG AAC GGA ACA AGG CAG AAA G-3′) and SacI-
fumI-rev (5′-TAT GAG CTC GCA GCA CCG GCG
AGT TGC ATT AAA ATG G-3′). Restriction sites are
in boldface and start or stop codons are in italics. Vec-
tor pET-30a(+) and the PCR product were digested with
NdeI and SacI, and ligated to form pET-30a-AT144HIS.
The encoded protein (48.3 kDa) comprises the FumI
sequence [GenBank: ACS27061] with a C-terminal
extension of ASSVDKLAAALEHHHHHH.
For expression without a 6xHis tag, fumI was ampli-
fied by PCR with NdeI-fumI-for and SacI-Stop-fumI-rev
(5′-TAT GAG CTC TTA AGC ACC GGC GAG TTG
CAT TAA AAT GG-3′) and cloned as above to give
pET-30a-AT144.
pMAL-AT144
The fumI gene was amplified by PCR using primers
BamHI-fumI-for (5′-AGC TAT GGA TCC ATG GCG
AAC GGA ACA AGG C-3′) and PstI-Stop-fumI-rev (5′-
CGC CTT CTG CAG TCA AGC ACC GGC GAG
TTG-3′), digested with BamHI and PstI, and cloned into
the same sites of vector pMAL-c2E. For cleavage of
MBP (42.6 kDa) from the fusion protein (89.5 kDa) after
affinity purification, the recognition site DDDDK for
recombinant enterokinase, which is located upstream of
the polylinker site in pMAL-c2E, was used.
Expression of the aminotransferase gene
Expression from pET vectors
Cultures were grown in Luria-Bertani (LB) medium (5
g/l yeast extract, 10 g/l tryptone, 10 g/l NaCl) supple-
mented with 50 μg/ml ampicillin to select for plasmids
derived from pET-3a, or 50 μg/ml kanamycin for plas-
mids derived from pET-30a(+) following the guidelines
provided by Novagen. Initially, the fumI gene was
expressed in E. coli BL21(DE3) from plasmid pET-30a-
AT144 by using a 2% inoculum of an overnight culture,
incubation at 37°C and 200 rpm until OD600 reached
1.0, addition of IPTG to a final concentration of 1 mM,
and continued incubation for 3 h. Cells were harvested
by centrifugation. For plasmid pET-3a-HISAT, several E.
coli strains were compared with protein expression per-
formed as above, except that induction was done with 0
μM, 10 μM, 50 μM, 100 μM, 200 μM, 400 μM or 1000
μM IPTG for E. coli Tuner, and 400 μM IPTG or no
IPTG for all other strains, and temperature was shifted
to 30°C after induction.
Expression as fusion protein with maltose-binding protein
Strains harboring plasmid pMAL-AT144 were grown
overnight at 37°C and 250 rpm in LB-medium with
0.2% glucose and 50 μg/ml ampicillin, diluted 50-fold in
the same medium, and incubated under the same condi-
tions until OD600 reached 0.4 - 0.6. IPTG was added to
a final concentration of 0.3 mM, and incubation was
continued for 2 h at 37°C, or for 20 h at 30°C or room
temperature (23.5°C).
Expression in E. coli ArcticExpress(DE3)
Cultivation conditions followed the guidelines provided
by Stratagene. Strains harboring pET-3a or pET-30a(+)
derived plasmids were grown overnight in LB medium
with 20 μg/ml gentamycin and the appropriate antibiotic
for the pET vector at 37°C and 250 rpm. The cultures
were diluted 50-fold in LB medium without antibiotics
and incubated for 3 h at 30°C and 250 rpm. The cul-
tures were then transferred to 11°C (Ecotron incubator,
Infors HT, Bottmingen, CH), and after 10 min of
temperature equilibration, IPTG was added to a final
concentration of 1 mM for pET-30a(+) or 0.4 mM for
pET-3a derived plasmids. The induced cultures were
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incubated at 11°C and 250 rpm for 24 h. For subsequent
chromatographic purification, fumI was expressed from
plasmid pET-30a-AT144HIS as above, except that a
modified M9ZB medium [66] was used, containing the
M9 salts, 10 g/l tryptone instead of NZ-amine, 5 g/l
yeast extract, 1 mM MgSO4 and 0.4% glucose.
Purification of the recombinant aminotransferase
Purification of the MBP-aminotransferase fusion protein
(MBP-FumI)
Pellets of 250-ml cultures were suspended in 10 ml of
binding buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM
EDTA, pH 7.4) and lysed by passing twice through a
French Press (Thermo Electron Corporation, Waltham,
MA, USA) at 20,000 psi cell pressure. The lysate was
clarified by centrifugation at 9,000 × g for 30 min and
4°C, filtered through a 0.45 μm filter (Millipore, Bedford,
MA, USA), and diluted 5-fold with binding buffer. Using
an ÄKTAprime system (GE Healthcare Life Sciences,
Uppsala, Sweden), 24 ml of that protein solution were
loaded at a flow rate of 0.5 ml/min onto two serially
connected 1-ml MBP Trap HP columns (GE Healthcare)
which were pre-equilibrated with 15 ml binding buffer.
After washing with 30 ml binding buffer, the fusion pro-
tein MBP-FumI was eluted with 10 ml of elution buffer
(20 mM Tris-HCl, 200 mM NaCl, 50 mM maltose, pH
7.4). Fractions of 0.5 ml were collected, analyzed by
SDS-PAGE using a 10% polyacrylamide gel, and those
containing MBP-FumI were pooled and dialyzed against
recombinant enterokinase (rEK) cleavage buffer (20 mM
Tris-HCl, 20 mM CaCl2, 50 mM NaCl, pH 7.4) for 20 h
at 4°C. To cleave the MBP tag, dialyzed MBP-FumI (120
μg/ml) was incubated with rEK at room temperature
(rEK:MBP-FumI ratio (unit:μg) = 1:40). After 6 h of
incubation, an equal amount of rEK was added again,
and incubation was continued for 18 h at room tem-
perature. Samples for SDS-PAGE analysis were taken
before addition of rEK, after 6 h and after 24 h. For
separation into soluble and insoluble fractions, samples
were centrifuged at 20,817 × g for 20 min at 4°C, and
the pellet was resuspended in the same volume of rEK
cleavage buffer.
Purification of the 6xHis-tagged aminotransferase by
immobilized nickel affinity chromatography
For the development of a purification protocol, the cell
pellets from 100-ml expression cultures of E. coli Arcti-
cExpress(DE3), producing aminotransferase from pET-
30a-AT144HIS with a C-terminal 6xHis tag, were resus-
pended in 40 ml of binding buffer (20 mM sodium
phosphate, 0.5 M NaCl, pH 7.4) containing 20 mM imi-
dazole, and lysed by passing through a French Press
twice at 20,000 psi cell pressure. The lysate was centri-
fuged at 9,000 × g for 30 min at 4°C. The filtered (0.45
μM) supernatant was divided into three aliquots and
imidazole was added to the aliquots to a final concentra-
tion of 20 mM (I), 60 mM (II) and 100 mM (III),
respectively. A 1-ml HisTrap HP column (GE Health-
care), pre-equilibrated with 5 ml binding buffer, was
loaded with 6 ml of an aliquot at a flow rate of 1 ml/
min using the ÄKTAprime system. The column was
washed with 10 ml (I), 12 ml (II) or 14 ml (III) of bind-
ing buffer containing 20 (I), 60 (II) or 100 mM (III) imi-
dazole. Proteins were eluted by increasing the imidazole
concentration to 500 mM in a linear gradient over
25 ml, and fractions of 1 ml were collected.
Purification at preparative scale was done by resus-
pending the cells from a 1-l culture (wet weight of cell
pellet: 10 g) in 10 ml of binding buffer with 60 mM imi-
dazole, and performing lysis, centrifugation and filtration
as above. The clear lysate was doubled in volume with
binding buffer containing 60 mM imidazole, and loaded
at a flow rate of 1 ml/min onto a 1-ml HisTrap HP col-
umn which was pre-equilibrated with 10 ml binding
buffer. After washing the column with 15 ml of binding
buffer, the recombinant protein was eluted by using a
linear gradient of 60 to 500 mM imidazole over 25 ml
elution buffer. Fractions of 2 ml were collected, and
those containing the protein were pooled, diluted with
imidazole-free binding buffer to a final concentration of
60 mM imidazole, and applied again to the re-equili-
brated column. Purification was performed as before,
except that the gradient elution was done with 50 ml
buffer. Fractions were analyzed by SDS-PAGE, those
containing aminotransferase in electrophoretically
homogeneous purity were pooled, and the protein
concentration was determined by the Bradford assay.
Protein analysis
For analysis of aminotransferase production and solubi-
lity, 1.5-ml samples of expression culture were centri-
fuged. The biomass was resuspended in 200 μl of
resuspension buffer (10 mM Tris-HCl, 25 mM EDTA
and 0.25% b-mercaptoethanol, pH 8.2), 50 μl of freshly
prepared lysozyme (100 mg/ml) were added, and the
mixture was incubated for 5 min at 37°C. After addition
of 750 μl Triton X-100, the mixture was incubated for
another 5 min at 37°C. To distinguish between soluble
and aggregated protein, a 100-μl sample of the lysate
was centrifuged at 20,817 × g for 20 min at 4°C. The
complete lysate, supernatant, and pellet after resuspen-
sion in the same volume of 10 mM Tris-HCl buffer (pH
8.2), were analyzed by SDS-PAGE as total, soluble and
insoluble protein fractions, respectively. The protein
samples were mixed 1:1 with 2× sample buffer (0.125 M
Tris-HCl, 4% SDS, 20% glycerol, 0.02% bromophenol
blue, 2% b-mercaptoethanol, pH 6.8) and heated 5 min
at 95°C. SDS-PAGE gel electrophoresis [67] was done
according to standard procedures [65] with a Hoefer SE
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260 mini-vertical gel electrophoresis unit (San Francisco,
CA, USA). Staining of SDS-PAGE gels was done either
with Coomassie Brilliant Blue R-250 or silver nitrate
according to standard procedures [65], or with GelCode
Blue Stain Reagent (Thermo Scientific, Rockford, IL,
USA) according to the manufacturer’s instructions.
Molecular weight marker BenchMark™ Protein Ladder
was provided by Invitrogen (Carlsbad, USA).
Western blotting [68] was carried out using the Wes-
ternPro Alkaline Phosphatase Chromogenic Detection
Kit (Peqlab, Erlangen, Germany) with the PerfectBlue
“Semi-Dry"-Electro Blotter (Peqlab) according to the
manufacturer’s instructions. Anti-His6 mouse monoclo-
nal antibody was obtained from Roche (Mannheim, Ger-
many) and was used at a final concentration of 0.4 μg/ml.
Protein concentrations were determined by the
method of Bradford [69] using the reagent provided by
Sigma. Bovine serum albumin (BSA) was used as
standard.
Enzyme activity assays
Biomass from E. coli expression cultures was harvested
by centrifugation at 4,500 × g for 10 min at 4°C, resus-
pended in the same volume of 20 mM Tris-HCl, 50
mM NaCl, 2 mM CaCl2 pH 7.4, and homogenized by
passing through a French pressure cell at 20,000 psi.
Enzyme activity was determined in the same buffer,
after doubling the volume, and using final concentra-
tions of 5 μM HFB1, 20 μM pyridoxal phosphate (PLP)
and 3 mM pyruvate.
Enzyme assays with purified MBP-FumI fusion protein
and purified His-tagged FumI were carried out in 20
mM Tris-HCl buffer pH 8.0, containing 0.067% BSA, 15
μM HFB1, 20 μM PLP and 5 mM pyruvate. The final
concentration of aminotransferase was 20 μg/ml. All
reaction mixtures were incubated in a water bath at
25°C, and samples from the reaction were inactivated at
99°C for 10 min.
Liquid chromatography-mass spectrometry (LC-MS)
In order to analyze samples from enzyme activity assays,
LC-MS measurements were performed. Samples were
centrifuged and 40-μl aliquots were dried at 50°C under
a stream of nitrogen, dissolved in 200 μl of solvent con-
taining 13C-FB1 as internal standard, and analyzed by
injecting 50 μl onto a Zorbax Eclipse XDB-C8 column
in an Agilent 1100 LC system coupled to an Agilent
1100 G1946 D mass spectrometer operating in the
selected ion monitoring (SIM) mode with positive elec-
trospray ionisation as previously described [1]. For inte-
gration of 2-keto-HFB1 into the method, a sample of
HFB1, which was reacted to completion with purified
His-tagged aminotransferase, was measured by HPLC-
MS in scan mode. A novel peak with m/z 427 [M+Na]+
as most intense ion and m/z 387 [M+H-H2O]
+ as sec-
ond most intense ion appeared at 11.5 min. In the next
step, fragmentor voltages were optimized by flow injec-
tion and m/z 427 and 387 were included into the origi-
nal SIM method. Ions and fragmentor voltages were as
follows: HFB1 quantifier: m/z 406.4, 120 V; HFB1 quali-
fier: m/z 334.4, 220 V; 13C-FB1 quantifier: 756.5, 150 V;
2-keto-HFB1 quantifier: m/z 427, 130 V; 2-keto-HFB1
qualifier: m/z 387, 90 V. For calibration, standard solu-
tions of FB1, HFB1 and 2-keto-HFB1 in the range of 0.05
to 2 μM containing 200 μg/l 13C-FB1 as internal stan-
dard were used.
Acknowledgements
We would like to thank Markus Kainz and Elisabeth Pichler from Quantas
Analytics GmbH (Tulln, Austria) for collaboration on LC-MS analysis. This
work was supported in part by the Austrian Research Promotion Agency
FFG and the Christian Doppler Research Association.
Author details
1BIOMIN Research Center, Technopark 1, 3430 Tulln, Austria. 2Institute of
Applied Microbiology, Department of Biotechnology, University of Natural
Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria. 3Center for
Analytical Chemistry, Department for Agrobiotechnology IFA-Tulln, University
of Natural Resources and Life Sciences, Vienna, Konrad Lorenz Strasse 20,
3430 Tulln, Austria. 4Food Biotechnology Laboratory, Department of Food
Sciences and Technology, University of Natural Resources and Life Sciences,
Muthgasse 18, 1190 Vienna, Austria.
Authors′ contributions
DoH and WDM designed the experiments and wrote the manuscript. DoH
performed the experiments. SH contributed some of the plasmids and,
together with RG, participated in the design of the research with a special
focus on recombinant gene expression without IPTG. HES developed the
method for analytical quantification of 2-keto-HFB1. GS provided helpful
discussion and expertise on mycotoxin biotransformation. DiH participated
in the design of the research with a special focus on the maltose-binding
protein fusion protein. All authors participated in editing the manuscript and
all have read and approved the final version.
Competing interests
A long term goal of the present work is to make the aminotransferase FumI
commercially available through BIOMIN GmbH for enzymatic detoxification
of fumonisins. However, while the information contained in the present
manuscript is of interest for those using microbial cell factories for enzyme
production, it is irrelevant for a commercial application of the enzyme.
Therefore, the authors declare no competing interests.
Received: 25 June 2010 Accepted: 18 August 2010
Published: 18 August 2010
References
1. Heinl S, Hartinger D, Thamhesl M, Kunz-Vekiru E, Krska R, Schatzmayr G,
Moll WD, Grabherr R: Degradation of fumonisin B1 by the consecutive
action of two bacterial enzymes. J Biotechnol 2010, 145:120-129.
2. Marasas WF: Fumonisins: history, world-wide occurrence and impact. Adv
Exp Med Biol 1996, 392:1-17.
3. Marasas WF: Discovery and occurrence of the fumonisins: a historical
perspective. Environ Health Perspect 2001, 109:239-243.
4. Binder EM, Tan LM, Chin LJ, Handl J, Richard J: Worldwide occurrence of
mycotoxins in commodities, feeds and feed ingredients. Anim Feed Sci
Technol 2007, 137:265-282.
5. Gelderblom WC, Jaskiewicz K, Marasas WF, Thiel PG, Horak RM, Vleggaar R,
Kriek NP: Fumonisins-novel mycotoxins with cancer-promoting activity
produced by Fusarium moniliforme. Appl Environ Microbiol 1988,
54:1806-1811.
Hartinger et al. Microbial Cell Factories 2010, 9:62
http://www.microbialcellfactories.com/content/9/1/62
Page 12 of 14
6. Bezuidenhout SC, Gelderblom WCA, Gorst-Allman CP, Horak RM,
Marasas WFO, Spiteller G, Vleggaar R: Structure elucidation of the
fumonisins, mycotoxins from Fusarium moniliforme. J Chem Soc Chem
Commun 1988, 743-745.
7. Marasas WF, Jaskiewicz K, Venter FS, Van Schalkwyk DJ: Fusarium
moniliforme contamination of maize in oesophageal cancer areas in
Transkei. S Afr Med J 1988, 74:110-114.
8. Harrison LR, Colvin BM, Greene JT, Newman LE, Cole JR: Pulmonary edema
and hydrothorax in swine produced by fumonisin B1, a toxic metabolite
of Fusarium moniliforme. J Vet Diagn Invest 1990, 2:217-221.
9. Kellerman TS, Marasas WF, Thiel PG, Gelderblom WC, Cawood M,
Coetzer JA: Leukoencephalomalacia in two horses induced by oral
dosing of fumonisin B1. Onderstepoort J Vet Res 1990, 57:269-275.
10. Gelderblom WC, Kriek NP, Marasas WF, Thiel PG: Toxicity and
carcinogenicity of the Fusarium moniliforme metabolite, fumonisin B1, in
rats. Carcinogenesis 1991, 12:1247-1251.
11. Rheeder JP, Marasas WFO, Thiel PG, Sydenham EW, Shephard GS, Van
Schalkwyk DJ: Fusarium moniliforme and fumonisins in corn in relation to
human esophageal cancer in Transkei. Phytopathology 1992, 82:353-357.
12. Ross PF, Ledet AE, Owens DL, Rice LG, Nelson HA, Osweiler GD, Wilson TM:
Experimental equine leukoencephalomalacia, toxic hepatosis, and
encephalopathy caused by corn naturally contaminated with
fumonisins. J Vet Diagn Invest 1993, 5:69-74.
13. Chu FS, Li GY: Simultaneous occurrence of fumonisin B1 and other
mycotoxins in moldy corn collected from the People’s Republic of China
in regions with high incidences of esophageal cancer. Appl Environ
Microbiol 1994, 60:847-852.
14. Hendricks K: Fumonisins and neural tube defects in South Texas.
Epidemiology 1999, 10:198-200.
15. Haschek WM, Gumprecht LA, Smith G, Tumbleson ME, Constable PD:
Fumonisin toxicosis in swine: an overview of porcine pulmonary edema
and current perspectives. Environ Health Perspect 2001, 109(Suppl
2):251-257.
16. Voss KA, Riley RT, Norred WP, Bacon CW, Meredith FI, Howard PC,
Plattner RD, Collins TF, Hansen DK, Porter JK: An overview of rodent
toxicities: liver and kidney effects of fumonisins and Fusarium
moniliforme. Environ Health Perspect 2001, 109(Suppl 2):259-266.
17. Marasas WF, Riley RT, Hendricks KA, Stevens VL, Sadler TW, Gelineau-van WJ,
Missmer SA, Cabrera J, Torres O, Gelderblom WC, Allegood J, Martinez C,
Maddox J, Miller JD, Starr L, Sullards MC, Roman AV, Voss KA, Wang E,
Merrill AH: Fumonisins disrupt sphingolipid metabolism, folate transport,
and neural tube development in embryo culture and in vivo: a potential
risk factor for human neural tube defects among populations
consuming fumonisin-contaminated maize. J Nutr 2004, 134:711-716.
18. Norred WP, Voss KA, Bacon CW, Riley RT: Effectiveness of ammonia
treatment in detoxification of fumonisin-contaminated corn. Food Chem
Toxicol 1991, 29:815-819.
19. Sydenham EW, Van der Westhuizen L, Stockenstrom S, Shephard GS,
Thiel PG: Fumonisin-contaminated maize: physical treatment for the
partial decontamination of bulk shipments. Food Addit Contam 1994,
11:25-32.
20. Jackson LS, Hlywka JJ, Senthil KR, Bullerman LB: Effect of thermal
processing on the stability of fumonisins. Adv Exp Med Biol 1996,
392:345-353.
21. Castelo MM, Sumner SS, Bullerman LB: Stability of fumonisins in thermally
processed corn products. J Food Prot 1998, 61:1030-1033.
22. De Girolamo A, Solfrizzo M, Visconti A: Effect of processing on fumonisin
concentration in corn flakes. J Food Prot 2001, 64:701-705.
23. Solfrizzo M, Carratu MR, Avantaggiato G, Galvano F, Pietri A, Visconti A:
Ineffectiveness of activated carbon in reducing the alteration of
sphingolipid metabolism in rats exposed to fumonisin-contaminated
diets. Food Chem Toxicol 2001, 39:507-511.
24. Avantaggiato G, Solfrizzo M, Visconti A: Recent advances on the use of
adsorbent materials for detoxification of Fusarium mycotoxins. Food
Addit Contam 2005, 22:379-388.
25. Voss KA, Smith GW, Haschek WM: Fumonisins: Toxicokinetics, mechanism
of action and toxicity. Anim Feed Sci Technol 2007, 137:299-325.
26. Blackwell BA, Gilliam JT, Savard ME, David Miller J, Duvick JP: Oxidative
deamination of hydrolyzed fumonisin B1 (AP1) by cultures of Exophiala
spinifera. Natural Toxins 1999, 7:31-38.
27. Duvick J, Maddox J, Gilliam J: Compositions and methods for fumonisin
detoxification. US Patent 6538177 Pioneer Hi-Bred. Int. (USA) 2003.
28. Merrill AH, Wang E, Gilchrist DG, Riley RT: Fumonisins and other inhibitors
of de novo sphingolipid biosynthesis. Adv Lipid Res 1993, 26:215-234.
29. Schmelz EM, Dombrink-Kurtzman MA, Roberts PC, Kozutsumi Y, Kawasaki T,
Merrill AH: Induction of apoptosis by fumonisin B1 in HT29 cells is
mediated by the accumulation of endogenous free sphingoid bases.
Toxicol Appl Pharmacol 1998, 148:252-260.
30. Humpf HU, Schmelz EM, Meredith FI, Vesper H, Vales TR, Wang E,
Menaldino DS, Liotta DC, Merrill AH: Acylation of naturally occurring and
synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-
palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed
fumonisin, AP1, and a new category of ceramide synthase inhibitor. J
Biol Chem 1998, 273:19060-19064.
31. Seiferlein M, Humpf HU, Voss KA, Sullards MC, Allegood JC, Wang E,
Merrill AH: Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro
and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites.
Mol Nutr Food Res 2007, 51:1120-1130.
32. Sorensen HP, Mortensen KK: Soluble expression of recombinant proteins
in the cytoplasm of Escherichia coli. Microb Cell Fact 2005, 4:1.
33. Waugh DS: Making the most of affinity tags. Trends Biotechnol 2005,
23:316-320.
34. Esposito D, Chatterjee DK: Enhancement of soluble protein expression
through the use of fusion tags. Curr Opin Biotechnol 2006, 17:353-358.
35. Schein CH, Noteborn MHM: Formation of Soluble Recombinant Proteins
in Escherichia coli is Favored by Lower Growth Temperature. Bio/
Technology 1988, 6:291-294.
36. Kolaj O, Spada S, Robin S, Wall JG: Use of folding modulators to improve
heterologous protein production in Escherichia coli. Microb Cell Fact 2009,
8:9.
37. Weickert MJ, Doherty DH, Best EA, Olins PO: Optimization of heterologous
protein production in Escherichia coli. Curr Opin Biotechnol 1996,
7:494-499.
38. Mergulhao FJ, Summers DK, Monteiro GA: Recombinant protein secretion
in Escherichia coli. Biotechnol Adv 2005, 23:177-202.
39. Georgiou G, Segatori L: Preparative expression of secreted proteins in
bacteria: status report and future prospects. Curr Opin Biotechnol 2005,
16:538-545.
40. Bessette PH, Aslund F, Beckwith J, Georgiou G: Efficient folding of proteins
with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc Natl
Acad Sci USA 1999, 96:13703-13708.
41. Rosano GL, Ceccarelli EA: Rare codon content affects the solubility of
recombinant proteins in a codon bias-adjusted Escherichia coli strain.
Microb Cell Fact 2009, 8:41.
42. Schultz T, Martinez L, de Marco A: The evaluation of the factors that
cause aggregation during recombinant expression in E. coli is simplified
by the employment of an aggregation-sensitive reporter. Microb Cell Fact
2006, 5:28.
43. Blackwell JR, Horgan R: A novel strategy for production of a highly
expressed recombinant protein in an active form. FEBS Lett 1991,
295:10-12.
44. Hammarstrom M, Hellgren N, van Den BS, Berglund H, Hard T: Rapid
screening for improved solubility of small human proteins produced as
fusion proteins in Escherichia coli. Protein Sci 2002, 11:313-321.
45. Kapust RB, Waugh DS: Escherichia coli maltose-binding protein is
uncommonly effective at promoting the solubility of polypeptides to
which it is fused. Protein Sci 1999, 8:1668-1674.
46. Shih YP, Kung WM, Chen JC, Yeh CH, Wang AH, Wang TF: High-
throughput screening of soluble recombinant proteins. Protein Sci 2002,
11:1714-1719.
47. Cho HJ, Lee Y, Chang RS, Hahm MS, Kim MK, Kim YB, Oh YK: Maltose
binding protein facilitates high-level expression and functional
purification of the chemokines RANTES and SDF-1alpha from Escherichia
coli. Protein Expr Purif 2008, 60:37-45.
48. Ferrer M, Chernikova TN, Yakimov MM, Golyshin PN, Timmis KN:
Chaperonins govern growth of Escherichia coli at low temperatures. Nat
Biotechnol 2003, 21:1266-1267.
49. Joseph RE, Andreotti AH: Bacterial expression and purification of
interleukin-2 tyrosine kinase: single step separation of the chaperonin
impurity. Protein Expr Purif 2008, 60:194-197.
Hartinger et al. Microbial Cell Factories 2010, 9:62
http://www.microbialcellfactories.com/content/9/1/62
Page 13 of 14
50. Thain A, Gaston K, Jenkins O, Clarke AR: A method for the separation of
GST fusion proteins from co-purifying GroEL. Trends Genet 1996,
12:209-210.
51. Rohman M, Harrison-Lavoie KJ: Separation of copurifying GroEL from
glutathione-S-transferase fusion proteins. Protein Expr Purif 2000, 20:45-47.
52. Karlovsky P: Biological detoxification of fungal toxins and its use in plant
breeding, feed and food production. Nat Toxins 1999, 7:1-23.
53. Fuchs E, Binder EM, Heidler D, Krska R: Structural characterization of
metabolites after the microbial degradation of type A trichothecenes by
the bacterial strain BBSH 797. Food Additives and Contaminants 2002,
19:379-386.
54. Molnar O, Schatzmayr G, Fuchs E, Prillinger H: Trichosporon
mycotoxinivorans sp. nov., a new yeast species useful in biological
detoxification of various mycotoxins. Syst Appl Microbiol 2004, 27:661-671.
55. Benedetti R, Nazzi F, Locci R, Firrao G: Degradation of fumonisin B1 by a
bacterial strain isolated from soil. Biodegradation 2006, 17:31-38.
56. Lei XG, Porres JM: Phytase enzymology, applications, and biotechnology.
Biotechnol Lett 2003, 25:1787-1794.
57. Li RY, Cheng CY: Investigation of inclusion body formation in
recombinant Escherichia coli with a bioimaging system. J Biosci Bioeng
2009, 107:512-515.
58. Ceroni A, Passerini A, Vullo A, Frasconi P: DISULFIND: a disulfide bonding
state and cysteine connectivity prediction server. Nucleic Acids Res 2006,
34:W177-W181.
59. Schlicke M, Brakmann S: Expression and purification of histidine-tagged
bacteriophage T7 DNA polymerase. Protein Expr Purif 2005, 39:247-253.
60. Picaud S, Olsson ME, Brodelius PE: Improved conditions for production of
recombinant plant sesquiterpene synthases in Escherichia coli. Protein
Expr Purif 2007, 51:71-79.
61. Nomine Y, Ristriani T, Laurent C, Lefevre JF, Weiss E, Trave G: Formation of
soluble inclusion bodies by hpv e6 oncoprotein fused to maltose-
binding protein. Protein Expr Purif 2001, 23:22-32.
62. Zanier K, Nomine Y, Charbonnier S, Ruhlmann C, Schultz P, Schweizer J,
Trave G: Formation of well-defined soluble aggregates upon fusion to
MBP is a generic property of E6 proteins from various human
papillomavirus species. Protein Expr Purif 2007, 51:59-70.
63. Schein CH: Production of soluble recombinant proteins in bacteria. Bio/
Technology 1989, 7:1141-1149.
64. Ferrer M, Chernikova TN, Timmis KN, Golyshin PN: Expression of a
temperature-sensitive esterase in a novel chaperone-based Escherichia
coli strain. Appl Environ Microbiol 2004, 70:4499-4504.
65. Sambrook J, Russell DW: Molecular cloning: A laboratory manual New York,
USA: Cold Spring Harbor Laboratory Press 2001.
66. Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW: Use of T7 RNA
polymerase to direct expression of cloned genes. Methods Enzymol 1990,
185:60-89.
67. Laemmli UK: Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 1970, 227:680-685.
68. Burnette WN: “Western blotting": electrophoretic transfer of proteins
from sodium dodecyl sulfate-polyacrylamide gels to unmodified
nitrocellulose and radiographic detection with antibody and
radioiodinated protein A. Anal Biochem 1981, 112:195-203.
69. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248-254.
doi:10.1186/1475-2859-9-62
Cite this article as: Hartinger et al.: Enhancement of solubility in
Escherichia coli and purification of an aminotransferase from
Sphingopyxis sp. MTA144 for deamination of hydrolyzed fumonisin B1.
Microbial Cell Factories 2010 9:62.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hartinger et al. Microbial Cell Factories 2010, 9:62
http://www.microbialcellfactories.com/content/9/1/62
Page 14 of 14
